Yuan Jian-Ming, Xiong Shao-Hu, Liu Zhen, Wen Yu, Dang Rui-Shan, Shen Man-Ru, Zhang Yong-Zhen, Zhang Xi, Yang Xiang-Qun, Zhang Chuan-Sen
Department of Anatomy, Second Military Medical University, Shanghai, People's Republic of China.
J Tissue Eng Regen Med. 2016 Jul;10(7):554-63. doi: 10.1002/term.1748. Epub 2013 Jul 31.
Tissue engineering has been considered a promising approach for creating grafts to replace autologous venous valves. Here, ovine bone marrow-derived endothelial progenitor cells (EPCs) and multipotent adult progenitor cells (MAPCs) were harvested and then loaded into decellularized venous matrix to create tissue-engineered (TE) valved vein. Subsequently, the ovine femoral veins containing the valve were removed and replaced by TE grafts or acellular matrix only. The morphology and function were analysed for up to 1 year by ultrasonography, angiography, H&E staining and scanning electron microscopy (SEM). The differentiation of seeded cells was traced immunofluorochemically. The results showed that decellularized venous matrix could initially and feebly attract endogenous cells, but failed afterwards and were insufficient to restore valve function. On the contrary, the seeded cells differentiated into endothelial cells (ECs) in vivo and formed a monolayer endothelium, and smooth muscle cells within the scaffold therefore produced TE grafts comparable to the native vein valve. This TE graft remained patent and sufficient after implantation into the venous circuit of the ovine lower extremity for at least 6 months. Unfortunately, cells seeded on the luminal surface and both sides of the leaflets lost their biological functions at 12 months, resulting in thrombosis formation and leading to complete occlusion of the TE grafts and impotent venous valves. These findings suggest that this TE valved venous conduit can function physiologically in vivo in the medium term. Before translating this TE venous valve into clinical practice, the durability should be improved and thrombogenicity should be suppressed. Copyright © 2016 John Wiley & Sons, Ltd.
组织工程被认为是一种很有前景的方法,可用于制造移植体以替代自体静脉瓣膜。在此,收集了绵羊骨髓来源的内皮祖细胞(EPC)和多能成人祖细胞(MAPC),然后将它们加载到去细胞化静脉基质中,以制造组织工程(TE)带瓣静脉。随后,切除包含瓣膜的绵羊股静脉,并用TE移植物或仅用脱细胞基质进行替换。通过超声检查、血管造影、苏木精和伊红(H&E)染色以及扫描电子显微镜(SEM)对形态和功能进行了长达1年的分析。通过免疫荧光化学方法追踪接种细胞的分化情况。结果表明,去细胞化静脉基质最初能够微弱地吸引内源性细胞,但随后失效,不足以恢复瓣膜功能。相反,接种的细胞在体内分化为内皮细胞(EC),形成单层内皮,因此支架内的平滑肌细胞产生了与天然静脉瓣膜相当的TE移植物。这种TE移植物植入绵羊下肢静脉回路后至少6个月保持通畅且功能良好。不幸的是,在小叶腔表面和两侧接种的细胞在12个月时失去了生物学功能,导致血栓形成,进而导致TE移植物完全闭塞和静脉瓣膜功能丧失。这些发现表明,这种TE带瓣静脉导管在中期可在体内发挥生理功能。在将这种TE静脉瓣膜转化为临床应用之前,应提高其耐久性并抑制血栓形成倾向。版权所有© 2016约翰威立父子有限公司。